Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully-integrated biopharmaceutical company with commercial products and a robust development pipeline, will ...

Mpox and Smallpox Threats: Vaccine Development and Biosecurity Policy ...

Such sectors provide resilience during potential economic slowdowns, making them attractive for investors seeking stability.

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at ...

U.S. stocks surged on Wednesday after President Donald Trump temporarily pulled back on most tariffs, deescalating trade war ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.75%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal ...

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal antibody candidate, in ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

Stock analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Tonix Pharmaceuticals in a report released on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz anticipates that ...